The specialist in small molecule drug development has highlighted data announced this week at the American Association of Cancer Research annual meeting by Sierra Oncology (NASDAQ:SRRA) the license holder for the Chk1 inhibitor SRA737 originally developed by Sareum. The oral presentation described significant anti-tumour activity when combined with anti-PD-L1 immunotherapy and low dose gemcitabine (LDG) in a mouse model of small cell lung cancer (SCLC). Immunotherapy, which harnesses our own
03 Apr 2019
Chk1, immunotherapy and LDG combo exhibits dramatic anti-tumour activity in pre-clinical model
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Chk1, immunotherapy and LDG combo exhibits dramatic anti-tumour activity in pre-clinical model
Sareum Holdings plc (SAR:LON) | 10.5 -0.4 (-27.6%) | Mkt Cap: 7.53m
- Published:
03 Apr 2019 -
Author:
Derren Nathan -
Pages:
8
The specialist in small molecule drug development has highlighted data announced this week at the American Association of Cancer Research annual meeting by Sierra Oncology (NASDAQ:SRRA) the license holder for the Chk1 inhibitor SRA737 originally developed by Sareum. The oral presentation described significant anti-tumour activity when combined with anti-PD-L1 immunotherapy and low dose gemcitabine (LDG) in a mouse model of small cell lung cancer (SCLC). Immunotherapy, which harnesses our own